LENSAR, Inc. (LNSR): Price and Financial Metrics


LENSAR, Inc. (LNSR): $6.99

0.03 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LNSR Stock Summary

  • LENSAR Inc's stock had its IPO on October 2, 2020, making it an older stock than merely 2.58% of US equities in our set.
  • The ratio of debt to operating expenses for LENSAR Inc is higher than it is for about merely 13.54% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.18 for LENSAR Inc; that's greater than it is for only 11.98% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LENSAR Inc are SUMO, IDN, ASAN, URGN, and ONDS.
  • To dig deeper into the stock's financial statements, go to LNSR's page on browse-edgar?action=getcompany&CIK=0001320350.

LNSR Valuation Summary

  • LNSR's price/sales ratio is 3.2; this is 71.81% lower than that of the median Healthcare stock.
  • Over the past 48 weeks, LNSR's EV/EBIT ratio has gone up 6.5.
  • LNSR's EV/EBIT ratio has moved up 6.5 over the prior 48 weeks.

Below are key valuation metrics over time for LNSR.

Stock Date P/S P/B P/E EV/EBIT
LNSR 2021-08-31 3.2 1.6 -4.6 -3.1
LNSR 2021-08-30 2.9 1.4 -4.2 -2.7
LNSR 2021-08-27 2.9 1.4 -4.2 -2.7
LNSR 2021-08-26 2.9 1.4 -4.1 -2.6
LNSR 2021-08-25 2.9 1.4 -4.2 -2.7
LNSR 2021-08-24 3.0 1.5 -4.3 -2.8

LNSR Price Target

For more insight on analysts targets of LNSR, see our LNSR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1 (Strong Buy)

LNSR Stock Price Chart Interactive Chart >

Price chart for LNSR

LNSR Price/Volume Stats

Current price $6.99 52-week high $8.98
Prev. close $6.96 52-week low $5.50
Day low $6.70 Volume 9,000
Day high $7.01 Avg. volume 10,690
50-day MA $7.34 Dividend yield N/A
200-day MA $7.03 Market Cap 76.79M

LENSAR, Inc. (LNSR) Company Bio


LENSAR, Inc. develops laser technologies. The Company provides autoprecision laser and proprietary 3-D imaging, measurement, and guidance system for refractive cataract surgery. LENSAR serves the healthcare industries throughout the United States.


LNSR Latest News Stream


Event/Time News Detail
Loading, please wait...

LNSR Latest Social Stream


Loading social stream, please wait...

View Full LNSR Social Stream

Latest LNSR News From Around the Web

Below are the latest news stories about LENSAR Inc that investors may wish to consider to help them evaluate LNSR as an investment opportunity.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and LENSAR (LNSR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and LENSAR (LNSR – Research Report). Globus Medical (GMED) JMP Securities analyst David Turkaly reiterated a Hold rating on Globus Medical today. The company's shares closed last Thursday at $72.05. According to TipRanks.

Christine Brown on TipRanks | March 3, 2022

LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ORLANDO, Fla., March 03, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2021 and provided an update on key strategic and operational initiatives.

Yahoo | March 3, 2022

LENSAR Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ALLY

ORLANDO, Fla., March 01, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its 510(k) submission for its next-generation ALLY™ Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY Adaptive Cataract Treatment System and is

Yahoo | March 1, 2022

LENSAR to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

ORLANDO, Fla., February 28, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2021 financial results will be released before market open on Thursday, March 3, 2022. LENSAR’s management will host a conference call and webcast at 8:30am ET on Thursday, March 3, 2022 to discuss the financial results

Yahoo | February 28, 2022

Should Now Consider Selling Your LENSAR (LNSR) Shares?

Merion Road Capital Management, an investment management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here. Merion Road Capital’s long-only large-cap portfolio returned 20% for the year. While this is a strong result on an absolute basis, it lagged the S&P. Spare some time to check the fund’s […]

Yahoo | February 23, 2022

Read More 'LNSR' Stories Here

LNSR Price Returns

1-mo -3.59%
3-mo 19.49%
6-mo 1.01%
1-year -15.48%
3-year N/A
5-year N/A
YTD 16.69%
2021 -17.38%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.482 seconds.